1. Development of Solidified Self-microemulsifying Delivery Systems Containing Tacrolimus for Enhanced Dissolution and Pharmacokinetic Profile.
- Author
-
Zeng L, Wang Y, Liu Z, Hu X, Zheng C, Yao L, Zhang M, Feng X, and Song H
- Subjects
- Animals, Male, Tablets, Drug Liberation, Rats, Rats, Sprague-Dawley, Silicon Dioxide chemistry, Hypromellose Derivatives chemistry, Tacrolimus pharmacokinetics, Tacrolimus administration & dosage, Tacrolimus chemistry, Solubility, Drug Delivery Systems, Emulsions, Immunosuppressive Agents pharmacokinetics, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents chemistry, Biological Availability
- Abstract
The use of tacrolimus (FK506) as an immunosuppressant is limited by its low aqueous solubility and bioavailability. The self-microemulsifying drug delivery system (SMEDDS) has successfully improved the solubility of FK506 in our previous study. This study focused on the solidification of liquid SMEDDS to capture the benefits of both liquid SMEDDS and solid dosage forms. Among several porous silica adsorbents evaluated, Aeroperl® 300 Pharma showed the best performance in terms of droplet size, in vitro dissolution, adsorbent-drug compatibility, and tabletabilities. And precoating the adsorbent with polyvinylpyrrolidone K30 resulted in complete drug release. Hydroxypropyl methylcellulose based matrix tablet was developed to achieve a sustained release of FK506. Differential scanning calorimetry and X-ray powder diffraction indicated that FK506 was present in a molecular or amorphous state in the solidified SMEDDS and tablets. In vivo pharmacokinetic studies showed that the self-prepared tablet had improved bioavailability (179.02%) compared to the marketed product Advagraf®. This study provided a promising candidate with improved dissolution and bioavailability for FK506 and a prospective platform for SMEDDS development., Competing Interests: Declarations. Ethics Statement: The animal experiments were approved by the 900 Hospital of the Joint Logistics Team Animal Care and Use Committee (Approval number 2023–052). Conflict of Interest: The authors declare that they have no known competing financial interests or personal relationships that might influence the work reported in this paper., (© 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.)
- Published
- 2024
- Full Text
- View/download PDF